Key statistics
As of last trade, Prelude Therapeutics Inc (PRLD:NSQ) traded at 2.55, 53.61% above the 52 week low of 1.66 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.55 |
---|---|
High | 2.55 |
Low | 2.55 |
Bid | 2.55 |
Offer | 2.63 |
Previous close | 2.55 |
Average volume | 686.64k |
---|---|
Shares outstanding | 55.02m |
Free float | 51.20m |
P/E (TTM) | -- |
Market cap | 140.31m USD |
EPS (TTM) | -1.80 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 14:30 BST.
More ▼
- Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
- Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
- Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
- Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
- Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
- Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
- Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
- Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
More ▼